Antagonizing the NF2-YAP pathway, which promotes ferroptosis by up-regulating modulators like ACSL4 and transferrin receptor (TFRC), offers a new perspective on treating mesenchymal or metastatic cancer cells, which are highly sensitive to ferroptosis (139). Here, TFRC is linked to metastatic malignant neoplasm.